Clinical and Molecular Prevalence of Lipodystrophy in an Unascertained Large Clinical Care Cohort

Lipodystrophies are a group of disorders characterized by absence or loss of adipose tissue and abnormal fat distribution, commonly accompanied by metabolic dysregulation. Although considered rare disorders, their prevalence in the general population is not well understood. We aimed to evaluate the clinical and genetic prevalence of lipodystrophy disorders in a large clinical care cohort. We interrogated the electronic health record (EHR) information of >1.3 million adults from the Geisinger Health System for lipodystrophy diagnostic codes. We estimate a clinical prevalence of disease of 1 in 20,000 individuals. We performed genetic analyses in individuals with available genomic data to identify variants associated with inherited lipodystrophies and examined their EHR for comorbidities associated with lipodystrophy. We identified 16 individuals carrying the p.R482Q pathogenic variant in LMNA associated with Dunnigan familial partial lipodystrophy. Four had a clinical diagnosis of lipodystrophy, whereas the remaining had no documented clinical diagnosis despite having accompanying metabolic abnormalities. We observed a lipodystrophy-associated variant carrier frequency of 1 in 3,082 individuals in our cohort with substantial burden of metabolic dysregulation. We estimate a genetic prevalence of disease of ∼1 in 7,000 in the general population. Partial lipodystrophy is an underdiagnosed condition. and its prevalence, as defined molecularly, is higher than previously reported. Genetically guided stratification of patients with common metabolic disorders, like diabetes and dyslipidemia, is an important step toward precision medicine.

[1]  D. Savage,et al.  What lipodystrophies teach us about the metabolic syndrome. , 2019, The Journal of clinical investigation.

[2]  N. Patni,et al.  Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. , 2019, Pathology.

[3]  B. Akıncı,et al.  Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities , 2018, Current Diabetes Reports.

[4]  Alexander E. Lopez,et al.  Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes , 2017, bioRxiv.

[5]  E. Chiquette,et al.  Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.

[6]  Matthew S. Lebo,et al.  A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a Large Research Cohort , 2017, bioRxiv.

[7]  C. Vigouroux,et al.  Clinical Utility Gene Card for: Familial partial lipodystrophy , 2017, European Journal of Human Genetics.

[8]  Zhen Wang,et al.  Clinical Features and Management of Non-HIV–Related Lipodystrophy in Children: A Systematic Review , 2017, The Journal of clinical endocrinology and metabolism.

[9]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[10]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[11]  Inês Barroso,et al.  Prospective functional classification of all possible missense variants in PPARG , 2016, Nature Genetics.

[12]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[13]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[14]  A. Garg.  Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .

[15]  S. O’Rahilly,et al.  Perilipin deficiency and autosomal dominant partial lipodystrophy. , 2011, The New England journal of medicine.

[16]  A. K. Agarwal,et al.  Lipodystrophies: disorders of adipose tissue biology. , 2009, Biochimica et biophysica acta.

[17]  R. Hegele,et al.  Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  A. Garg,et al.  Genetic disorders of adipose tissue development, differentiation, and death. , 2006, Annual review of genomics and human genetics.

[19]  A. Garg,et al.  Laminopathies: multisystem dystrophy syndromes. , 2006, Molecular genetics and metabolism.

[20]  A. Garg.  Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.

[21]  Jimmy D Bell,et al.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.

[22]  J. Papp,et al.  Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13 , 2001, Nature Genetics.

[23]  R. Hegele,et al.  LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration. , 2000, The Journal of clinical endocrinology and metabolism.

[24]  R. Hegele,et al.  Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. , 2000, Genome research.

[25]  M. Lovett,et al.  Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. , 2000, American journal of human genetics.

[26]  S. Gregory,et al.  LMNA, encoding lamin A/C, is mutated in partial lipodystrophy , 2000, Nature Genetics.

[27]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[28]  A. Garg,et al.  Lipodystrophy Syndromes. , 2016, Endocrinology and metabolism clinics of North America.

[29]  A. Bowcock,et al.  AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.

[30]  A. Bowcock,et al.  Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene. , 2001, The Journal of clinical endocrinology and metabolism.

[31]  R. Hegele,et al.  Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. , 2000, Human molecular genetics.